



() -

*

**

()

)

(

)

(

(P> /)

(P> /)

(P< /)

(P> /)

(P< /)

(P> /)

(P< /)

()
)
 .((Desferal or Deferoxamine mesylate)
 .()
 .()
 () Deferiprone (DFP or L1) ()
 .()
 () .()
 .()
 .()
 .() (Compliance) (Adherence)
 .()
 .()
 ()
 ()
 () (Affective) (Cognitive) ()

/

/

)

()

(

()

(Enzymatic Immunoassay)

()

Dynex Technology

/

SPSS

(SPSS Inc., Chicago, IL, USA)

(Mc Nemar)

(P> /)

(P> /) /

(/)

(/)

(/)

) /

(/)

)

(/

(/)

(/

(/)

(/)

(/)

)

(/)

(P< /

/

/

(/)

)

(P> /)

(P> /

(

(/)

(/)

(% /)

(% /)

(% /) *

(% /)

(% /) ζ

(% /)

(% /) *

(% /)

(% /)

(% /)

(% /) *

(% /)

(% /)

(% /)

(% /)

(% /)

ξ

P< / *
P< / ζ
ξ

(P> /)

(P> /)

()

(/)

()

()

()

(/)

()

)

(/)

(

)

)

(

()

(P< /

)

(P< /

()

(/)

)

(P< /

(P> /

)

()

()

()

)

(

(P< /

)

()

(P> /)

()

()

()

)

/

()

(

()

()

()

()

()

()

()

()

.() " (dysphonic mood)

.()

.()

.()

"
"

.()

.()

.()

.()

()

.()

(Reminder technique)

()

()

()

()

()

()

()

()

References:

1. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. *Circulation* 1964; 30: 698-705.
2. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. *N Engl J Med* 1994; 331: 567-73
3. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. *N Engl J Med* 1994; 331: 567-73.
4. Victor HA. Deferiprone therapy for transfusional iron overload. *Best Pract Res Clin Haematol* 2005; 18: 299-317.
5. Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. *Pediatr Blood Cancer* 2005; 44: 500-7.
6. Porter JB. A risk-benefit assessment of iron-chelation therapy. *Drug Saf* 1997; 17:407-21.
7. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. *Hematology (Am Soc Hematol Educ Program)* 2001;1: 47-61.
8. Meo A, Ruggeri A, La Rosa MA, et al. Long-term treatment with deferiprone in a L1 veteran. *Eur J Haematol.* 2005; 74: 523-5.
9. Porter JB, Abeyasinghe RD, Marshall L, et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy. *Blood* 1996; 88: 705-14.

10. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. *Eur J Haematol* 2005; 74: 217-20.
 11. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. *JAMA* 2002; 288: 2880-3.
 12. Puckett MJ, Russell ML. The role of the allied health professional in improving patient adherence. *J Allied Health* 1978; 7: 36-41.
 13. Willey C. Behavior-changing methods for improving adherence to medication. *Curr Hypertens Rep* 1999; 1: 477-81.
 14. Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. *Semin Hematol* 2001; 38 Suppl 1: 77-84.
 15. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. *J Am Pharm Assoc* 2003; 43: 668-78.
 16. Burke LE, Dunbar-Jacob J. Adherence to medication, diet, and activity recommendations: from assessment to maintenance. *Cardiovasc Nurs*. 1995; 9: 62-79.
 17. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. *JAMA* 2002; 288: 2868-79.
 18. Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. *Annu Rev Nurs Res*. 2000; 18: 48-90.
 19. Sherman M, Koch D, Giardina P, et al. Thalassaemic children's understanding of illness: a study of cognitive and emotional factors. *Ann N Y Acad Sci*. 1985; 445: 327-36.
 20. Schaffer SD, Yoon SJ. Evidence-based methods to enhance medication adherence. *Nurse Pract* 2001; 26:44, 50, 52, 54.
 21. Angastiniotis M. The adolescent thalassaemic. The complicant rebel. *Minerva Pediatr*. 2002; 54: 511-5.
 22. Goldbeck L, Baving A, Kohne E. Psychosocial aspects of beta-thalassemia: distress, coping and adherence. *Klin Padiatr*. 2000; 212: 254-9.
 23. Koch DA, Giardina PJ, Ryan M, et al. Behavioral contracting to improve adherence in patients with thalassemia. *J Pediatr Nurs*. 1993; 8: 106-11.
 24. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. *BMC Clin Pharmacol*. 2002; 2:3. <http://www.biomedcentral.com/1472-6904/2/3>
 25. Linda Carman Copel. Health education and promotion. In: Suzanne C. Smeltzer, Brenda G. Bare. Brunner & Suddarth's Textbook of Medical-Surgical Nursing. 9th ed. Philadelphia: J.B Lippincott Co, 2000, 40-50
- ۲۶
27. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. *N Engl J Med* 2000; 343: 327-31.
 28. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. *Am J Hematol*. 1993; 42: 81-5.
 29. Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. *Eur J Haematol*. 2005; 74: 93-100.
 30. van Oost BA, van den Beld B, Cloin LG, et al. Measurement of ferritin in serum: application in diagnostic use. *Clin Biochem* 1984; 17:263-9.